Coherus BioSciences, Inc. (NASDAQ:CHRS) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants McDavid Stilwell - CFO Denny Lanfear - President, CEO, and Chairman Paul Reider - CCO Theresa LaVallee - CDO Conference Call Participants Balaji Prasad - Barclays Jason Gerberry - Bank of America Georgi Yordanov - Cowen and Company Operator Good day, and thank you for standing by. Welcome to the Coherus Biosciences Inc. First Quarter 2022 Earnings Conference Call. At this time, all participan ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact name ...

| --- | --- | |----------------------------|-------------------| | | | | | | | | | | | | | Coherus | BioSciences, Inc. | | Analyst Day March 29, 2022 | | | | | | | | Copyright ©2022 All Rights Reserved. Forward-Looking Statements Except for the historical information discussed today and contained herein and in the accompanying video, the matters discussed today and set forth in this presentation and in the accompanying video are forward-looking statements within the meaning of the "safe harbor" provisions o ...

Coherus BioSciences March 2022 Copyright ©2022 All Rights Reserved. Forward Looking Statements Except for the historical information discussed today and contained herein, the matters discussed today and set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding achieving future cash flows in our biosimilar portfolio; our long term growth; our abil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-36721 Coherus BioSci ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q4 2021 Earnings Conference Call February 17, 2022 5:00 PM ET Company Participants Denny Lanfear - President, Chief Executive Officer and Chairman McDavid Stilwell - Chief Financial Officer Paul Reider - Chief Commercial Officer Theresa LaVallee - Chief Development Officer Conference Call Participants Salim Syed - Mizuho Georgi Yordanov - Cowen and Company Chris Schott - JPMorgan Balaji Prasad - Barclays Jason Gerberry - Bank of America Merrill Lynch Douglas Tsao - H ...

Coherus BioSciences January 10, 2022 Copyright ©2022 All Rights Reserved. Forward Looking Statements Except for the historical information discussed today and contained herein, the matters discussed today and set forth in this presentation are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding achieving future cash flows in our biosimilar portfolio; our long term growth; ou ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Q3 2021 Earnings Conference Call November 8, 2021 5:00 PM ET Company Participants McDavid Stilwell - CFO Dennis Lanfear - Chairman, President & CEO Paul Reider - EVP, Commercial Operations and Market Access Conference Call Participants Salim Syed - Mizuho Securities Kenneth Cacciatore - Cowen and Company Christopher Schott - JPMorgan Chase & Co. Douglas Tsao - H.C. Wainwright & Co. Jason Gerberry - Bank of America Merrill Lynch Balaji Prasad - Barclays Bank Operator G ...

Table of Contents Title of each class Trading Symbol(s) Name of each exchange on which registered UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36721 Coherus BioSciences, Inc. (Exact ...

JUPITER-06: A Randomized, Double-blind, Phase 3 Study of Toripalimab versus Placebo In Combination with First-Line Chemotherapy for Treatment Naive Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) R.-H. Xu1, F. Wang1, C. Cui2, J. Yao3, Y. Zhang4, G. Wang5, J. Feng6, S. Yang7, Y. Fan8, J. Shi9, X.Zhang10, L. Shen11, Y.Shu12, C. Wang13, T. Dai14, T. Mao15, L. Chen16, Z. Guo17, B. Liu18, H. Pan19, Coherus Biosciences and Shanghai Junshi Biosciences. 1Department of Medical Oncology, Sun Yat-Sen ...